M2 is a metabolite of the chemopreventive agent oltipraz. Oltipraz metabolite M2 has been shown to inhibit liver steatosis by inhibiting lipogenesis and enhancing mitochondrial function, including fuel oxidation. Oltipraz metabolite M2 acts as a potent inhibitor of LXRa transcriptional activity, and also AMPK activator inducing the phosphorylation of AMPK.
M2 is a metabolite of the chemopreventive agent oltipraz; LXRa inhibitor; AMPK activator.
Caratteristiche e vantaggi
This compound is featured on the AMPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication in vitro (ED50 approximately 10 microM), undergoes extensive metabolism in vivo. Most of the orally administered drug undergoes opening of the dithiolethione ring, reduction, recyclization, and methylation to form 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine
Clinical pharmacology and therapeutics, 88(3), 360-368 (2010-07-29)
Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo[1,2-a]pyrazine (RM)) were evaluated after single-dose (30-90 mg) and multiple-dose (60 mg b.i.d. or
The AMP-activated protein kinase (AMPK) acts as a sensor of cellular energy status. AMPK exists as heterotrimeric complexes comprising a catalytic α subunit and regulatory β and γ subunits.
Domande
Recensioni
★★★★★ Nessuna valutazione
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
